Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | SAT1 | P21673 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22548516 | 1.00 | CYP2C19 (0.52) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL24759345 | 0.98 | CYP2C19 (0.50) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL23842136 | 0.98 | CYP2C19 (0.50) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL23868460 | 0.93 | CYP2C19 (0.50) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL3825697 | 0.93 | CYP2C19 (0.50) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL5933282 | 0.90 | TSHR (0.46) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL11507752 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL23221203 | 0.84 | CYP2C19 (0.40) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL22421817 | 0.84 | TSHR (0.52) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL20626604 | 0.84 | TSHR (0.46) | CYP2C19CYP1A2MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-10611791-B2 | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, method for producing polynucleotide, polynucleotide, and method for producing binding nucleic acid molecule | NEC SOLUTION INNOVATORS, LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
| EP-1290002-A1 | CHEMICAL PRODUCTS SUITED FOR USE AS CO-CATALYSTS, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1280600-A2 | SUPPORTED CATALYST SYSTEM COMPRISING A METALLOCENE, A LEWIS-BASE AND AN ORGANODEMENTAL COMPOUND OF MAIN GROUP III, AND ITS USE | Basell Polypropylen GmbH (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001090112-A1 | CHEMICAL PRODUCTS SUITED FOR USE AS CO-CATALYSTS, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001047635-A2 | SUPPORTED CATALYST SYSTEM CONTAINING A METALLOCENE, A LEWIS BASE AND AN ELEMENTALLY ORGANIC COMPOUND OF MAIN GROUP III AND THE USE THEREOF | BASELL POLYPROPYLEN GMBH (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | CYP2C19 381/4885CYP1A2 158/4885MEN1 1512/4885 |
| US-10611791-B2 | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, method for producing polynucleotide, polynucleotide, and method for producing binding nucleic acid molecule | SNRPA1, SNRPB2, NSUN3 | CYP2C19 2882/4885CYP1A2 1999/4885MEN1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.